<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010072740">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Paboriboune, P.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Vial, Thomas</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Chassagne, F.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Sitbounlang, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Soundala, S.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Bertani, Stéphane</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Sengmanothong, D.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Babin, F. X.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Steenkeste, N.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Deny, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Pineau, P.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Deharo, Eric</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>A seven-year retrospective study on the surveillance of hepatitis B in Laos</title>
        <secondary-title>International Journal of Hepatology</secondary-title>
      </titles>
      <pages>art. ID 9462475 [11 ]</pages>
      <keywords>
        <keyword>LAOS</keyword>
      </keywords>
      <dates>
        <year>2018</year>
      </dates>
      <call-num>fdi:010072740</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>International Journal of Hepatology</full-title>
      </periodical>
      <isbn>2090-3448</isbn>
      <accession-num>ISI:000430270700001</accession-num>
      <electronic-resource-num>10.1155/2018/9462475</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010072740</url>
        </related-urls>
        <pdf-urls>
          <url>https://horizon.documentation.ird.fr/exl-doc/pleins_textes/divers18-05/010072740.pdf</url>
        </pdf-urls>
      </urls>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Objective. Lao PDR is one of the most highly endemic countries for hepatitis B in Asia and the second country for liver cancer incidence. Therefore, the follow-up of infected individuals through predictive serological markers is of utmost importance to monitor the progression of the pathology and take the decision on treatment. Methods. A retrospective-descriptive cohort study was conducted on 3,857 HBV-infected patients. Information about infection status (viral load, VL), liver function (aminotransferases), and treatments was recorded. Results. M/F sex ratio was 1.77 for a median age of 37. Patients under 37 displayed higher VL than older ones and men had higher VL than women. Initial VL ranged from &lt;50 IU/mL to 2.5 10(13) IU/mL. Median aminotransferase values were 45.5 U/L for ALAT and 44 U/L for ASAT, ranging from &lt;8 to &gt;2,000 U/L. Men had higher aminotransferase than women. Globally 20% of patients received treatment (mainly immunostimulant and reverse-transcriptase inhibitors); 11% had high levels of VL and liver enzymes, but only 2% of them were treated. Conclusion. Public health decisions should be taken urgently to rationalise vaccination and provide fair access to early diagnosis and treatment; otherwise the burden of HBV-associated diseases will be overwhelming for Laos in the near future.</abstract>
      <custom6>050 ; 052</custom6>
      <custom1>UR152</custom1>
      <custom7>Laos</custom7>
    </record>
  </records>
</xml>
